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Resolving PI3K-δ inhibitor resistance in CLL 
Ulf Klein   UNIVERSITY OF LEEDS 
Summary: 
In this issue of Blood, Scheffold and Chelliah Jebaraj et al identify enhanced signalling 
through IGF1R as the resistance mechanism of CLL cells to a PI3K-δ inhibitor in a CLL 
animal model. They also show that the inhibition of IGF1R provides a salvage treatment for 
PI3K-δ inhibitor-resistant tumors.   
Main text: 
Recent successes in cancer treatment by targeted therapies are partly undermined by the 
development of resistance to the therapies. Therefore, it is imperative to unravel the 
underlying molecular resistance mechanisms in order to develop salvage therapies. Specific 
targeting of pathways comprising PI3K-signalling has revolutionized the treatment of chronic 
lymphocytic leukemia (CLL) and provides a paradigm of targeted therapy for the mode-of-
action of pathway-specific drugs and for the identification of resistance mechanisms.1-3  
Drugs inhibiting two components of the PI3K-pathway, ibrutinib (targeting BrutonÕs-tyrosine 
kinase; BTK) and idelalisib (targeting phosphoinositide-3-kinase-δ; PI3K-δ) are highly 
efficacious in the treatment of CLL and other non-Hodgkin lymphomas (Fig.1A). However, 
whereas recent studies have uncovered causes of ibrutinib-resistance,4,5 the mechanism of 
resistance to idelalisib has remained elusive. 
Scheffold et al addressed this deficiency by modelling resistance to PI3K-δ inhibitors in vivo 
in two murine serial adoptive-transfer and treatment models.6 First, CLL cells derived from 
the commonly used Eµ-TCL1 CLL-model were transplanted into syngeneic mice, thus 
ensuring the presence of an intact tumor-microenvironment. Second, an Eµ-TCL1 CLL-
derived, well-characterized cell line (TCL1-192)7 was transplanted into NOD/SCID mice. The 
authors observed in both models that mice treated with PI3K-δ-inhibitor, while initially 
benefiting from PI3K-δ-inhibition, eventually succumbed to the disease. Scheffold and 
colleagues then used the experimentally more amenable TCL1-192 line to develop a serial-
transfer and treatment scheme to continuously treat CLL in vivo, thus generating tumors 
resistant to PI3K-δ-inhibition that were then subjected to whole-exome sequencing (WES). 
Naturally, the expectation was to identify mutations in PI3K-δ that abolish the action of the 
inhibitor, or recurrent activating genetic alterations in pathway genes downstream of PI3K-δ. 
However, the WES-analysis did not identify any single recurrent mutation in PI3K-δ,6 which 
was particularly surprising since mutations in BTK at the inhibitor-binding site are the 
hallmark of ibrutinib-resistant CLL.4,5 Also, no recurrent mutations were found in other genes. 
Similarly, CLL cells from patients that progressed under idelalisib-treatment were found to be 
devoid of unifying recurrent mutations that could explain drug resistance.8 
Scheffold et al then transcriptionally profiled these tumors and identified several genes 
whose expression was deregulated in PI3K-δ inhibitor-resistant vs. sensitive tumors.6 
Upregulated expression of insulin-like growth factor-1 receptor (IGF1R) showed the 
strongest association with resistance. They then demonstrated that IGF1R-upregulation 
indeed contributed to PI3K-δ-inhibitor resistance (Fig.1B). But, how is IGF1R-upregulation in 
the resistant cells mediated?            
Following a report showing that IGF1R can be transcriptionally activated by FOXO1 and 
GSK3,9 the authors investigated their potential role in PI3K-δ-inhibitor resistance.6 Indeed, 
the upregulation of IGF1R-expression was found to be attenuated by inhibition of GSK3 or 
FOXO1, indicating that enhanced IGF1R-expression upon PI3K-δ-inhibitor resistance is at 
least partially mediated by GSK3-activity that causes increased nuclear localization of 
FOXO1. Furthermore, the authors provided evidence that IGF1R promotes tumor-cell growth 
through activation of the MAPK-pathway. 
Next, Scheffold and colleagues investigated whether PI3K-δ-inhibitor resistance can be 
overcome by pharmacological inhibition of IGF1R with linsitinib.6 They demonstrated in well-
conceived in vitro and in vivo experiments that the combination of linsitinib with PI3K-δ-
inhibitors, but not linsitinib-only treatment, was toxic for PI3K-δ-inhibitor-resistant CLL cells 
(Fig.1C). Linsitinib-only treatment did not impair tumor-cell growth as IGF1R-expression was 
downregulated in PI3K-δ inhibitor-resistant cells in the absence of PI3K-δ-inhibitor. This 
downregulation is likely due to reactivation of PI3K/AKT-signaling which inhibits nuclear 
translocation of FOXO1. Conversely, in the combination treatment, PI3K/AKT-inhibition 
leads to GSK3 and FOXO1-activation that enhances expression of IGF1R-protein which is 
then targeted by linsitinib. Overall, the results indicate that IGF1R-upregulation promotes cell 
growth of PI3K-δ inhibitor-resistant CLL cells via activation of the MAPK-pathway, and 
consequently that PI3K-δ-inhibitor resistance could be overcome by simultaneous PI3K-
δ/IGF1R-inhibition.   
Now, what is the translational aspect? Ideally, one would similarly analyze idelalisib-resistant 
CLL cells from patients enrolled in an ongoing trial. This could conclusively validateÑor 
refuteÑthe clinical relevance of the findings. This major undertaking is the authorsÕ future 
aim. However, they may be on the right track: In one patientÕs CLL-sample with high IGF1R-
expression after 10-months of idelalisib-treatment, the authors could demonstrate in vitro 
that those cells showed a low response to PI3K-δ-inhibitor and that idelalisib/linsitinib-
combination treatment synergistically impaired cell growth, indicating that co-inhibition of 
IGF1R can sensitise tumor cells with reduced sensitivity to PI3K-δ inhibitors.6 Another 
finding may be equally relevant: Some untreated CLL patients showed high IGF1R-
expression in the tumor cells, particularly in association with trisomy-12. Also those patients 
may benefit from idelalisib/linsitinib-combination treatment.  
The present work highlights the importance of animal models in the identification of drug-
resistance mechanisms. Although it remains to be determined to what extent the newly 
identified IGF1R-mediated PI3K-δ-inhibitor resistance mechanism plays a role in idelalisib-
resistance in human CLL, the results provide a clear indication of what to keep an eye out for 
in clinical trials. The work also emphasizes that resistance mechanisms may not be 
restricted solely to genetic mutations. However, one caveat of modelling drug resistance in 
mice is the much shorter experimental time-span of disease progression compared to 
humans and the impact this may have on clonal evolution of the tumor. This could be 
particularly relevant in the case of PI3K-δ-inhibition, which was shown to increase genomic 
instability in B-cells and may thus introduce mutations by enhanced activity of activation-
induced cytidine deaminase, which normally initiates somatic hypermutation and class 
switching, in off-target genes.10 Since idelalisib can be administered for a very long time, 
there is the potential to uncover additional resistance mechanisms that involve genetic 
alterations which activate tumor-promoting pathways. In this context, it will be interesting to 
integrate the findings of the genomic analyses from mice6 and humans8 as this may uncover 
pathways that contribute to PI3K-δ-inhibitor resistance in some CLL-cases. Clearly, this 
excellently conducted work has provided a wealth of information and intriguing new leads 
that will be instrumental in overcoming the problem of idelalisib-resistance in human CLL 
and other malignancies. In the short term, the primary focus should be on determining 
whether linsitinib turns out to be the ideal companion of idelalisib in the treatment of 
lymphoid tumors with IGF1R-upregulation due to PI3K-δ-inhibitor resistance.   
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FIGURE LEGEND 
Figure 1: Model for the effects of the PI3K-δ-inhibitor idelalisib and the IGF1R-inhibitor 
linsitinib on PI3K-δ inhibitor-sensitive and resistant CLL cells. (A) PI3K-δ is activated by the 
B-cell receptor (Ag, antigen) and inhibited by idealisib, thus ablating the PI3K pathway-
mediated growth and survival program that activates AKT-signaling which is required for CLL 
cell survival. (B) Upregulation of IGF1R-expression via GSK3 and FOXO1 activates the 
MAPK pathway-mediated growth and survival program, thus leading to CLL cell survival. It is 
not known what leads to the activation of GSK3 and FOXO1 in PI3K-δ inhibitor-resistant CLL 
cells; however, FOXO1-activation is normally inhibited by AKT-signaling downstream of the 
PI3K-pathway. (C) Inhibition of IGF1R by linsitinib abolishes the MAPK-mediated growth and 
survival program, causing cell death in PI3K-δ-resistant CLL cells. The simultaneous 
inhibition of PI3K-δ is required since reactivation of PI3K/AKT-signaling leads to FOXO1-
inhibition and failure to upregulate IGF1R. In the serial adoptive-transfer and treatment 
experiments, Scheffold et al used the specific PI3K-δ-inhibitor GS-649443 (rather than 
idelalisib) as this has favourable pharmacokinetic properties in mice.   
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